Roivant Sciences Ltd. (ROIV) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to a loss of $0.13 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +9.43%. A quarter ago, it was expected that this company would post a loss of $0.27 per share when it actually produced a loss of $0.28, delivering a surprise of -3.7%.Over the last four quarters, the company has s ...

Roivant Sciences (NasdaqGS:ROIV) Q3 2026 Earnings call February 06, 2026 08:00 AM ET Company ParticipantsBenjamin Zimmer - CEOMatt Gline - CEOStephanie Lee - Head of Investor RelationsNone - Company RepresentativeConference Call ParticipantsAlexander Thompson - Managing Director, and Senior Equity Research AnalystAshwani Verma - Executive Director of SMID Biotech and Biopharma, and Equity Research AnalystBrian Cheng - Executive Director, and Senior Biotech AnalystCorinne Johnson - Managing Director of Equit ...

Roivant Sciences (NasdaqGS:ROIV) Q3 2026 Earnings call February 06, 2026 08:00 AM ET Company ParticipantsBenjamin Zimmer - CEOMatt Gline - CEOStephanie Lee - Head of Investor RelationsNone - Company RepresentativeConference Call ParticipantsAlexander Thompson - Managing Director, and Senior Equity Research AnalystAshwani Verma - Executive Director of SMID Biotech and Biopharma, and Equity Research AnalystBrian Cheng - Executive Director, and Senior Biotech AnalystCorinne Johnson - Managing Director of Equit ...

Roivant Sciences (NasdaqGS:ROIV) Q3 2026 Earnings call February 06, 2026 08:00 AM ET Speaker6Good day, and thank you for standing by. Welcome to the Roivant Third Quarter 2025 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question during the session, you will need to press star 11 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw you ...

Financial Results and Business Update for the Quarter Ended December 31, 2025 February 6, 2026 Disclaimer This presentation is intended for the investor community only; it is not intended to promote the product candidates referenced herein or otherwise influence healthcare prescribing decisions. For investor audiences only 2 Forward-Looking Statements This presentation includes forward-looking statements that are subject to substantial risks and uncertainties that could cause actual results to differ materi ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q _________________________________________________ (Mark One) ROIVANT SCIENCES LTD. (Exact name of Registrant as specified in its Charter) _________________________________________________ Bermuda 98-1173944 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 7th Floor 50 Broadway London SW1H 0DB United Kingdom Not Applicable ☒ QUARTERLY REPORT PURSUANT TO SECTIO ...

Exhibit 99.1 Roivant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (CS) and Reports Financial Results for the Third Quarter Ended December 31, 2025 BASEL, Switzerland and LONDON and NEW YORK, February 6, 2026 – Roivant (Nasdaq: ROIV) today announced positive Phase 2 results for brepocitinib in cutaneous sarcoidosis (CS) and reported its financial results for the third quarter ended December 31, 2025. "2025 was a transformative year for Roivant, driven by the quality of our cli ...

Brepocitinib 45 mg significantly improved cutaneous sarcoidosis disease activity, achieving a 22.3-point improvement in mean CSAMI-A at Week 16 versus a 0.7-point improvement in placebo (Δ21.6 P<0.0001). Brepocitinib demonstrated rapid, deep and sustained improvements across all other efficacy endpoints measured with consistent safety profilePriovant plans to progress CS to a pivotal program with a Phase 3 study starting in calendar year 2026 following engagement with the FDA, representing the third indicat ...

PHocus enrollment completed in under 12 months from first patient dosed, representing a rapid enrollment pace in pulmonary hypertension associated with interstitial lung diseaseTopline results on track for second half of calendar year 2026 WALTHAM, Mass., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Pulmovant, a clinical-stage biotechnology company committed to transforming the lives of patients with pulmonary diseases, and a Roivant (Nasdaq: ROIV) company, today announced that it has completed enrollment in the Phase ...

Brepocitinib 45 mg significantly improved cutaneous sarcoidosis disease activity, achieving a 22.3-point improvement in mean CSAMI-A at Week 16 versus a 0.7-point improvement in placebo (Δ 21.6 P<0.0001)All brepocitinib 45 mg patients achieved a clinically meaningful response, with 100% demonstrating at least a 10-point improvement on CSAMI-AOn the Investigator’s Global Assessment (IGA), 69% percent of brepocitinib 45 mg patients compared to 0% of placebo patients achieved the gold standard two-point improv ...